MARKET

CLVS

CLVS

Clovis Oncology
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.62
-0.08
-1.19%
After Hours: 6.62 0 0.00% 19:56 07/10 EDT
OPEN
6.66
PREV CLOSE
6.70
HIGH
6.84
LOW
6.55
VOLUME
2.32M
TURNOVER
--
52 WEEK HIGH
17.37
52 WEEK LOW
2.930
MARKET CAP
582.02M
P/E (TTM)
-0.9206
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 10 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CLVS stock price target is 13.63 with a high estimate of 32.00 and a low estimate of 4.000.

EPS

CLVS News

More
Hedge Funds Never Been Less Bullish On Clovis Oncology Inc (CLVS)
Insider Monkey · 06/30 19:46
Citigroup Option Alert: Jul 2 $55 Calls Sweep (43) near the Ask: 509 @ $1.119 vs 1484 OI; Earnings 7/14 Before Open Ref=$52.37
Benzinga · 06/25 19:08
Is Clovis Oncology (CLVS) Stock a Solid Choice Right Now?
Zacks · 06/23 13:37
New Preclinical Data on ALKS 4230 in Combination With Lucitanib to be Presented at 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II
PR Newswire · 06/22 14:01
Alkermes Highlights New Preclinical Data On ALKS 4230 In Combo With Lucitanib Presented At AACR
 Alkermes plc (NASDAQ:ALKS) and Clovis Oncology, Inc. (NASDAQ:CLVS) today announced positive preclinical data from a study designed to evaluate the combination potential of ALKS 4230, Alkermes'
Benzinga · 06/22 13:19
Clovis Oncology to Highlight Rubraca® (rucaparib) and Lucitanib Non-Clinical Data at the AACR Virtual Annual Meeting II 2020
Business Wire · 06/17 13:00
Biogen's NURTURE Data, And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha - Article · 06/16 08:55
The Daily Biotech Pulse: Sorrento Submits EUA Application For Rapid Coronavirus Test, Decision Day For Viela, Lantern Pharma IPO
Benzinga · 06/11 13:12

Industry

Biotechnology & Medical Research
-0.39%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Symbol
Price
%Change

About CLVS

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product Rubraca (rucaparib), an oral small molecule inhibitor of poly adenosine diphosphate (ADP)-ribose polymerase (PARP), is marketed in the United States for two indications specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The Company also provides Lucitanib, which is an investigational, oral, potent inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors one through three (VEGFR1-3), platelet-derived growth factor receptors alpha and beta, and fibroblast growth factor receptors one through three (FGFR1-3).
More

Webull offers kinds of Clovis Oncology Inc stock information, including NASDAQ:CLVS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLVS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CLVS stock methods without spending real money on the virtual paper trading platform.